LIVIVO - Search results -

Search results

Result 1 - 10 of total 897

Search options

Article ; Online: Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.

Megna, Matteo / Patruno, Cataldo / Bongiorno, Maria Rita / Gambardella, Alessio / Guarneri, Claudio / Romita, Paolo / Raimondo, Annunziata / Loconsole, Francesco / Fabbrocini, Gabriella

Clinical drug investigation

2022 Volume 42, Issue 6, Page(s) 525–531

Abstract: ... therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, as well in inactive ... and hepatitis C. This patient had not undergone hepatitis B prophylaxis or hepatitis C treatment ...

Abstract	Background and objective: Biologics for psoriasis, especially anti-tumor necrosis factor-α therapies, may reactivate hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, as well in inactive carriers or patients with occult infection. However, some biologics, including anti-interleukin-17 therapies such as secukinumab, seem to be less likely to cause hepatitis reactivation. This study assessed the safety of secukinumab treatment in patients with psoriasis with HBV or HBC infection. Methods: This was a retrospective cohort study of patients with moderate-to-severe psoriasis treated with secukinumab at seven Italian centers. Patients serologically positive for one or more of the following viral hepatitis markers were included: HCV antibody (± HCV-RNA positivity) and/or hepatitis B surface antigen, and/or HBV core antibody and/or HBV surface antibody (± HBV-DNA positivity). Patients received secukinumab 300 mg subcutaneously at week 0/1/2/3/4 then every 4 weeks; prophylactic therapy before starting secukinumab was prescribed where indicated. The primary study endpoint was the reactivation of hepatitis viral infection, defined as conversion to HBV-DNA or HCV-RNA positivity, with or without elevation of transaminases. Results: Sixty patients (17 with concomitant psoriatic arthritis) were included. Thirteen subjects were hepatitis B surface antigen positive, 19 were HBV core antibody positive, and 30 were positive for the HCV antibody; however, all were HCV-RNA negative. After 53.5 ± 37.5 weeks of secukinumab therapy, hepatitis reactivation occurred in only one patient, who had a reactivation of both hepatitis B and hepatitis C. This patient had not undergone hepatitis B prophylaxis or hepatitis C treatment before secukinumab. Conclusions: These real-world data support the safety of secukinumab in patients with positive markers of HBV or HCV infection, when administered together with dedicated prophylaxis.
MeSH term(s)	Antibodies, Monoclonal, Humanized ; Antiviral Agents/therapeutic use ; Biological Products/adverse effects ; DNA, Viral ; Hepacivirus/physiology ; Hepatitis B/chemically induced ; Hepatitis B/diagnosis ; Hepatitis B/drug therapy ; Hepatitis B Surface Antigens/pharmacology ; Hepatitis B Surface Antigens/therapeutic use ; Hepatitis B virus/physiology ; Hepatitis B, Chronic/drug therapy ; Hepatitis C/drug therapy ; Humans ; Psoriasis/drug therapy ; RNA/pharmacology ; RNA/therapeutic use ; Retrospective Studies ; Virus Activation
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Biological Products ; DNA, Viral ; Hepatitis B Surface Antigens ; RNA (63231-63-0) ; secukinumab (DLG4EML025)
Language	English
Publishing date	2022-05-28
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	1220136-4
ISSN	1179-1918 ; 0114-2402 ; 1173-2563
ISSN (online)	1179-1918
ISSN	0114-2402 ; 1173-2563
DOI	10.1007/s40261-022-01163-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2807: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era.

Rossetti, Barbara / Loggi, Elisabetta / Raffaelli, Chiara Spertilli / Mercinelli, Simona / Gandolfo, Claudia / Savellini, Gianni Gori / Galli, Silvia / Vitale, Giovanni / Di Donato, Roberto / Vukotic, Ranka / Grandini, Elena / Margotti, Marzia / Guarneri, Valeria / Furlini, Giuliano / Re, Maria Carla / De Luca, Andrea / Andreone, Pietro / Galli, Claudio / Cusi, Maria Grazia

The new microbiologica

2021 Volume 44, Issue 2, Page(s) 89–94

Abstract: Hepatitis C virus (HCV) Core Antigen (HCVAg) and HCV-RNA were tested in 962 plasma/serum samples ...

Abstract	Hepatitis C virus (HCV) Core Antigen (HCVAg) and HCV-RNA were tested in 962 plasma/serum samples from 180 patients during Direct Antiviral Agents (DAAs) treatment and at follow-up. One hundred and eighty individuals were included: 71% carried advanced fibrosis and 43% were treatment-experienced. A Sustained Virological Response (SVR) was achieved in 166/180 (92%) individuals: 96/102 (94.1%) na ve and 70/78 (89.7%) treatment-experienced (p=0.20). The baseline median levels of HCV-RNA and HCVAg were not significantly different between individuals achieving SVR (5.92 x 105 IU/mL, IQR 5.4-6.4, and 3,417 fmol/L, 2,900-3,795) and those without SVR (6.06 x 105 IU/mL, 5.63-6.57, and 3,391 fmol/L, 2,828-4,077). The HCV-RNA vs. HCVAg assays results showed a fair correlation with an overall moderate qualitative agreement (kappa=0.52). Among treatment-failed individuals, at failure 100% of the assays results were positive for both techniques, with HCV-RNA median value 3.09 x 105 IU/mL (2.10-29.09) and HCVAg median value 1570.28 fmol/L (360.15-9317.67). Undetectable HCV-RNA at EOT showed sensitivity 54%, specificity 100%, negative predictive value (NPV) 93% and positive predictive value (PPV) 100%. Undetectable HCVAg at EOT showed sensitivity 74%, specificity 100%, NPV 97% and PPV 100%. The operative and economic advantages of the HCVAg support the alternative use of HCVAg to monitor DAAs treatment outcome.
Language	English
Publishing date	2021-05-21
Publishing country	Italy
Document type	Journal Article
ZDB-ID	756168-4
ISSN	1121-7138 ; 0391-5352
ISSN	1121-7138 ; 0391-5352
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2267: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Early biochemical predictors of clinically relevant pancreatic fistula after distal pancreatectomy: a role for serum amylase and C-reactive protein.

Pecorelli, Nicolò / Guarneri, Giovanni / Palucci, Marco / Gozzini, Lorenzo / Vallorani, Alessia / Crippa, Stefano / Partelli, Stefano / Falconi, Massimo

Surgical endoscopy

2022 Volume 36, Issue 7, Page(s) 5431–5441

Abstract: ... POD) 1, and drain fluid amylase (DFA) and C-reactive protein (CRP) were evaluated on POD 2 and 3 ...

Abstract	Background: Recent evidence suggests that pancreatic inflammation plays a pivotal role in the occurrence of clinically relevant postoperative pancreatic fistula (CR-POPF) after pancreaticoduodenectomy but few data are available for distal pancreatectomy (DP). The aim of this study was to evaluate the impact of early biochemical markers on the occurrence of CR-POPF after DP. Methods: Clinical and laboratory data for 432 consecutive DP patients were reviewed. Serum amylase was evaluated on postoperative day (POD) 1, and drain fluid amylase (DFA) and C-reactive protein (CRP) were evaluated on POD 2 and 3. Receiver operator characteristic (ROC) curves were performed for all biochemical markers and an area under the curve (AUC) was computed. Multivariable regression analyses to identify the factors associated with CR-POPF and severe postoperative morbidity (Clavien-Dindo grade ≥ 3) were performed. Results: At 90 days after surgery, CR-POPF occurred in 155 (36%) patients, severe complications in 66 (15%) patients. ROC curve analyses showed that DFA on POD2 had the largest AUC (0.753, p < 0.001), followed by serum amylase on POD 1 (0.651, p < 0.001), serum CRP on POD3 (0.644, p < 0.001), and CRP change between POD 2 and POD 3 (0.644, p < 0.001). Multivariable analysis identified male gender (OR 2.29, 95% CI 1.36-3.86; p = 0.002), DFA ≥ 1500 U/L on POD2 (OR 4.63, 95% CI 2.72-7.89; p < 0.001), serum amylase ≥ 100 U/L on POD 1 (OR 1.72, 95% CI 1.01-2.93; p = 0.046), and CRP increase by at least 25 mg/L on POD 3 compared to the previous day (OR 1.89, 95% CI 1.11-3.21; p = 0.019) as independent predictors of CR-POPF, yielding a valid regression model (AUC 0.765, 95% CI 0.714-0.816, p < 0.001). Conclusions: Postoperative serum amylase and CRP trajectory represent useful early biochemical markers for CR-POPF in addition to DFA. Our findings suggest that these laboratory tests should be incorporated into clinical practice to aid postoperative patient and drain management.
MeSH term(s)	Amylases ; Biomarkers ; C-Reactive Protein ; Drainage/adverse effects ; Humans ; Male ; Pancreatectomy/adverse effects ; Pancreatic Fistula/epidemiology ; Pancreaticoduodenectomy/adverse effects ; Postoperative Complications/epidemiology ; Risk Factors
Chemical Substances	Biomarkers ; C-Reactive Protein (9007-41-4) ; Amylases (EC 3.2.1.-)
Language	English
Publishing date	2022-01-06
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	639039-0
ISSN	1432-2218 ; 0930-2794
ISSN (online)	1432-2218
ISSN	0930-2794
DOI	10.1007/s00464-021-08883-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2214: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with Direct-Acting Antiviral therapy.

Cacciola, Irene / Borgia, Francesco / Filomia, Roberto / Pitrone, Concetta / Franzè, Maria Stella / Alibrandi, Angela / Squadrito, Giovanni / Guarneri, Claudio / Papaianni, Valeria / Cannavò, Serafinella Patrizia / Raimondo, Giovanni

Journal of viral hepatitis

2019 Volume 27, Issue 3, Page(s) 333–337

Abstract: Apart from chronic liver disease, hepatitis C virus (HCV) may be responsible for several extra ...

Abstract	Apart from chronic liver disease, hepatitis C virus (HCV) may be responsible for several extra-hepatic manifestations. Its involvement in psoriasis development is still controversial. The aim of this study was to evaluate the possible effect of anti-HCV direct-acting antiviral (DAA) treatment on cutaneous psoriasis. Thirty-seven consecutive HCV patients with cutaneous psoriasis underwent efficacious DAA treatment, and all of them were efficiently cured as shown by HCV RNA negativity 24 weeks after stopping therapy (PT24W). An expert dermatologist evaluated the skin lesions at baseline, end of treatment (EOT) and PT24W using the psoriasis area severity index (PASI) scoring system. The impact on quality of life was measured with the Dermatologic Quality of Life Index (DLQI). Six patients had a stable disease throughout the study period, whereas 31/37 patients (83.8%) showed a significant improvement of the skin lesions at EOT (P < .0001). However, 24 of these 31 patients (77.4%) had a dramatic worsening of the psoriatic lesions at PT24W compared with EOT (P < .001), with lesion severity comparable to baseline. The outcome of psoriasis during and after treatment was independent of baseline PASI score, age, sex, HCV genotype, liver disease stage and of the presence of arterial hypertension, diabetes and autoimmune diseases. In conclusion, DAA-based HCV cure has only a transient effect on skin lesions of patients with concomitant cutaneous psoriasis.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antiviral Agents/therapeutic use ; Female ; Hepacivirus/drug effects ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/drug therapy ; Humans ; Male ; Middle Aged ; Prospective Studies ; Psoriasis/drug therapy ; Psoriasis/virology ; Quality of Life ; Skin/drug effects ; Skin/pathology ; Skin/virology ; Sustained Virologic Response ; Treatment Outcome
Chemical Substances	Antiviral Agents
Language	English
Publishing date	2019-11-26
Publishing country	England
Document type	Journal Article
ZDB-ID	1212497-7
ISSN	1365-2893 ; 1352-0504
ISSN (online)	1365-2893
ISSN	1352-0504
DOI	10.1111/jvh.13230
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4119: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.

Loggi, Elisabetta / Galli, Silvia / Vitale, Giovanni / Di Donato, Roberto / Vukotic, Ranka / Grandini, Elena / Margotti, Marzia / Guarneri, Valeria / Furlini, Giuliano / Galli, Claudio / Re, Maria Carla / Andreone, Pietro

PloS one

2017 Volume 12, Issue 11, Page(s) e0187755

Abstract: ... the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct ...

Abstract	Aim: To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs). Methods: Ninety-six patients treated with DAAs, either alone (91) or in combination with PEG interferon (5), were tested for HCV-RNA and for HCV-Ag at baseline and at weeks 2, 4, 8 and 12 during treatment and 12 weeks after completion. The concordance and correlation between the viral parameters as well as the respective kinetics during and after treatment were evaluated. Results: A sustained viral response (SVR) was achieved in 82 patients (91%), whereas 11 relapsed (R) and 1 showed a virological breakthrough while receiving treatment. HCV-RNA and HCV-Ag showed good concordance (kappa = 0.62) and correlation. No significant differences between SVR and R was observed in either assay at 2 and 4 weeks after the start of treatment. At 8 weeks, HCV-Ag showed higher accuracy than HCV-RNA (AUC: 0.74 vs. 0.55) and there was a significantly greater decrease from baseline in SVR than in R (4.01 vs. 3.36 log10; p<0.05). Conclusions: Monitoring during treatment with DAAs by using either HCV-RNA or HCV-Ag has only a limited predictive value for SVR. Since those assays are equivalent for identifying a virological relapse, HCV-Ag may be preferred from an economical and organizational perspective.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antiviral Agents/therapeutic use ; Female ; Hepatitis Antibodies/blood ; Hepatitis C/drug therapy ; Hepatitis C/genetics ; Humans ; Interferon-alpha/therapeutic use ; Male ; Middle Aged ; Ribavirin/therapeutic use ; Viral Load
Chemical Substances	Antiviral Agents ; Hepatitis Antibodies ; Interferon-alpha ; Ribavirin (49717AWG6K)
Language	English
Publishing date	2017-11-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0187755
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: NIR associated to PLS and SVM for fast and non-destructive determination of C, N, P, and K contents in poultry litter.

Bedin, Flavia Chiamulera Borsatti / Faust, Mateus Vinicius / Guarneri, Giovanni Alfredo / Assmann, Tangriani Simioni / Lafay, Cintia Boeira Batista / Soares, Lisiane Fernandes / de Oliveira, Paulo Armando Victória / Dos Santos-Tonial, Larissa Macedo

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

2020 Volume 245, Page(s) 118834

Abstract: ... destructive, and low-cost alternative. This study aims to estimate the C, N, P, and K content ... an alternative method for non-destructive C, N, P, and K determination in poultry samples. The regression models using ...

Abstract	Using near-infrared (NIR) spectroscopy for poultry litter characterization can be a rapid, non-destructive, and low-cost alternative. This study aims to estimate the C, N, P, and K content in poultry litter samples using for first time NIR spectroscopy. For these purposes, the building models were carried out using Partial Least Squares (PLS) and Support Vector Machines (SVM) methods. A total of 160 litter samples were analyzed in poultry houses of different rearing systems, seeking the highest possible variability in their chemical composition. NIR spectroscopy, combined with PLS and SVM methods, is an alternative method for non-destructive C, N, P, and K determination in poultry samples. The regression models using SVM provide better accuracy for all elements, laying the basis for the nonlinear regression approach's application. The K determination on poultry litter using NIR was possible only by the SVM model (R
Language	English
Publishing date	2020-08-26
Publishing country	England
Document type	Journal Article
ZDB-ID	210413-1
ISSN	1873-3557 ; 0370-8322 ; 0584-8539 ; 1386-1425
ISSN (online)	1873-3557
ISSN	0370-8322 ; 0584-8539 ; 1386-1425
DOI	10.1016/j.saa.2020.118834
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Bonn / Germany

Z 51/98: Show issues
Z 1611 a: Show issues
924/340: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reply Letter - Cupping therapy: a final therapeutic step in Persian medicine.

Guarneri, C

European review for medical and pharmacological sciences

2021 Volume 25, Issue 17, Page(s) 5329

MeSH term(s)	Cupping Therapy ; Medicine, Chinese Traditional
Language	English
Publishing date	2021-09-17
Publishing country	Italy
Document type	Letter ; Comment
ZDB-ID	605550-3
ISSN	2284-0729 ; 1128-3602 ; 0392-291X
ISSN (online)	2284-0729
ISSN	1128-3602 ; 0392-291X
DOI	10.26355/eurrev_202109_26639
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1887: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.

Musolino, A / Naldi, N / Dieci, M V / Zanoni, D / Rimanti, A / Boggiani, D / Sgargi, P / Generali, D G / Piacentini, F / Ambroggi, M / Cagossi, K / Gianni, L / Sarti, S / Bisagni, G / Ardizzoni, A / Conte, P F / Guarneri, V

The pharmacogenomics journal

2016 Volume 16, Issue 5, Page(s) 472–477

Abstract: ... A), lapatinib (arm B) or both (arm C). Genotyping was successfully performed in 73/121 (60%) pts. A significant ... improvement in pathological complete response (pCR) rate was observed for the combination arm C, but only ... in FcγRIIIa V allele carriers (C vs A, 67 vs 27%, P=0.043; C vs B, 67 vs 22%, P=0.012). An independent ...

Abstract	Lapatinib enhances antibody-dependent cell-mediated cytotoxicity (ADCC) activity of trastuzumab. FcγR polymorphisms have been associated with both ADCC and clinical activity of trastuzumab in HER2+ breast cancer (BC) patients (pts). We analyzed FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms in the CHER-LOB trial population of HER2+ BCs treated with preoperative chemotherapy plus trastuzumab (arm A), lapatinib (arm B) or both (arm C). Genotyping was successfully performed in 73/121 (60%) pts. A significant improvement in pathological complete response (pCR) rate was observed for the combination arm C, but only in FcγRIIIa V allele carriers (C vs A, 67 vs 27%, P=0.043; C vs B, 67 vs 22%, P=0.012). An independent interaction between arm C and FcγRIIIa V allele was found for pCR (odds ratio=9.4; 95% confidence interval, 2.3-39.6; P=0.003). No significant associations were observed between pCR and FcγRIIa polymorphism, and between pre-treatment tumor-infiltrating lymphocytes and FcγR polymorphisms. Our study provides evidence for a FcγRIIIa V allele-restricted pCR benefit from neoadjuvant trastuzumab plus lapatinib in HER2+ BC.
MeSH term(s)	Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Breast Neoplasms/drug therapy ; Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Breast Neoplasms/immunology ; Chemotherapy, Adjuvant ; Clinical Trials, Phase II as Topic ; Disease-Free Survival ; Female ; Gene Frequency ; Genotype ; Humans ; Mastectomy ; Middle Aged ; Neoadjuvant Therapy ; Pharmacogenetics ; Pharmacogenomic Testing ; Pharmacogenomic Variants ; Phenotype ; Polymorphism, Single Nucleotide ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Quinazolines/adverse effects ; Quinazolines/therapeutic use ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/analysis ; Receptors, IgG/genetics ; Retrospective Studies ; Time Factors ; Trastuzumab/adverse effects ; Trastuzumab/therapeutic use ; Treatment Outcome
Chemical Substances	Biomarkers, Tumor ; FCGR3A protein, human ; Fc gamma receptor IIA ; Protein Kinase Inhibitors ; Quinazolines ; Receptors, IgG ; lapatinib (0VUA21238F) ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
Language	English
Publishing date	2016-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	2106831-8
ISSN	1473-1150 ; 1470-269X
ISSN (online)	1473-1150
ISSN	1470-269X
DOI	10.1038/tpj.2016.51
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5806: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.

Elisabetta Loggi / Silvia Galli / Giovanni Vitale / Roberto Di Donato / Ranka Vukotic / Elena Grandini / Marzia Margotti / Valeria Guarneri / Giuliano Furlini / Claudio Galli / Maria Carla Re / Pietro Andreone

PLoS ONE, Vol 12, Iss 11, p e

2017 Volume 0187755

Abstract: To evaluate the potential value of using a serological assay to quantitate the hepatitis C ... virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct ...

Abstract	To evaluate the potential value of using a serological assay to quantitate the hepatitis C virus core antigen (HCV-Ag) when monitoring patients with chronic hepatitis C being treated with direct-acting antivirals (DAAs).Ninety-six patients treated with DAAs, either alone (91) or in combination with PEG interferon (5), were tested for HCV-RNA and for HCV-Ag at baseline and at weeks 2, 4, 8 and 12 during treatment and 12 weeks after completion. The concordance and correlation between the viral parameters as well as the respective kinetics during and after treatment were evaluated.A sustained viral response (SVR) was achieved in 82 patients (91%), whereas 11 relapsed (R) and 1 showed a virological breakthrough while receiving treatment. HCV-RNA and HCV-Ag showed good concordance (kappa = 0.62) and correlation. No significant differences between SVR and R was observed in either assay at 2 and 4 weeks after the start of treatment. At 8 weeks, HCV-Ag showed higher accuracy than HCV-RNA (AUC: 0.74 vs. 0.55) and there was a significantly greater decrease from baseline in SVR than in R (4.01 vs. 3.36 log10; p<0.05).Monitoring during treatment with DAAs by using either HCV-RNA or HCV-Ag has only a limited predictive value for SVR. Since those assays are equivalent for identifying a virological relapse, HCV-Ag may be preferred from an economical and organizational perspective.
Keywords	Medicine ; R ; Science ; Q
Subject code	360
Language	English
Publishing date	2017-01-01T00:00:00Z
Publisher	Public Library of Science (PLoS)
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Relation of C-reactive protein to oxidative stress and to endothelial activation in essential hypertension.

Cottone, Santina / Mulè, Giuseppe / Nardi, Emilio / Vadalà, Anna / Guarneri, Marco / Briolotta, Chiara / Arsena, Rosalia / Palermo, Alessandro / Riccobene, Raffaella / Cerasola, Giovanni

American journal of hypertension

2006 Volume 19, Issue 3, Page(s) 313–318

Abstract: Background: C-reactive protein (CRP) predicts cardiovascular outcome. Oxidative stress is ...

Abstract	Background: C-reactive protein (CRP) predicts cardiovascular outcome. Oxidative stress is considered to be involved in endothelial alteration. We hypothesized that in essential hypertension (EH), oxidative stress, as measured by 8-iso-prostaglandin-F(2alpha) (8-iso-PGF(2alpha)), should be associated with increased CRP and endothelial activation, as evaluated by soluble intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) plasma levels. Methods: In 83 subjects with mild EH and in 50 healthy control subjects we measured, in basal conditions, plasma levels of hs-CRP, 8-iso-PGF(2alpha), ICAM-1 and VCAM-1, and tumor necrosis factor-alpha (TNF-alpha). Results: Subjects with EH had higher levels of 8-iso-PGF(2alpha) (P < .0001), CRP (P < .001), ICAM-1 and VCAM-1 (P < .001), and TNF-alpha (P < .001) than did control subjects. We divided successively EH according to CRP values (<1, 1-3, >3 mg/L), and we observed increasing and significantly different levels of the endothelial parameters and of TNF-alpha along with increasing CRP. Linear analysis of correlation pointed out significant correlation of CRP with 8-iso-PGF(2alpha) (r = 0.730, P < .001), ICAM-1 and VCAM-1 (r = 0.642 and 0.468, P < .001 respectively), and TNF-alpha (r = 0.609, P < .001). Multiple regression analysis using CRP as a dependent variable confirmed the relationship of CRP with systolic blood pressure (beta 0.216, P = 0.039) and with 8-iso-PGF(2alpha) (beta 0.602, P = .0001). Conclusions: Our data demonstrate that in EH, inflammatory molecules such as CRP and TNF-alpha are increased and related to both oxidative stress and endothelial activation.
MeSH term(s)	Adult ; C-Reactive Protein/metabolism ; Case-Control Studies ; Endothelium, Vascular/metabolism ; Female ; Humans ; Hypertension/blood ; Hypertension/metabolism ; Intercellular Adhesion Molecule-1/blood ; Male ; Middle Aged ; Oxidative Stress/physiology ; Prostaglandins F/blood ; Regression Analysis ; Tumor Necrosis Factor-alpha/metabolism ; Vascular Cell Adhesion Molecule-1/blood
Chemical Substances	Prostaglandins F ; Tumor Necrosis Factor-alpha ; Vascular Cell Adhesion Molecule-1 ; Intercellular Adhesion Molecule-1 (126547-89-5) ; C-Reactive Protein (9007-41-4)
Language	English
Publishing date	2006-03
Publishing country	United States
Document type	Journal Article
ZDB-ID	639383-4
ISSN	1879-1905 ; 0895-7061
ISSN (online)	1879-1905
ISSN	0895-7061
DOI	10.1016/j.amjhyper.2005.09.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2329: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito